PLOS Genetics

DNA study sheds light on Scotland's Picts, and resolves some myths about them

Retrieved on: 
Tuesday, May 2, 2023
People, Picts, Genetic variation, DNA, Male, Female, University, Mitochondrion, IBD, Culture, PLOS Genetics, Ecclesiastical History, Woman, English people, Research, Cell, Cemetery, Balintore, Genetics, Chromosome, Population, Iron Age, Lundin Links, Knowledge, AD, Family, British Iron Age, Jewellery, Weaving, Forestry, Tea, Black Sea

They lived in Scotland during the early medieval period, from around AD300 to AD900, but many aspects of their society remain mysterious.

Key Points: 
  • They lived in Scotland during the early medieval period, from around AD300 to AD900, but many aspects of their society remain mysterious.
  • Our genetic study of human remains from this period challenges several myths about the Picts.
  • We attempted to shed light on the Picts’ origins and legacy by sequencing whole genomes – the full complement of DNA in human cells – from skeletons excavated at two cemeteries.

Stone monuments

    • These cemeteries, at Balintore in Easter Ross and Lundin Links in Fife, date to between the 5th and 7th centuries AD.
    • The Balintore burials are not well understood, but Lundin Links is characterised by exceptional stone monuments.
    • The burials take the form of round or rectangular cairns – where numerous stones are piled up as markers – and long cists.

Origin myths

    • Our findings support a prevailing view that the Picts descended from Iron Age groups in Britain and Ireland.
    • This contrasts with older, often elaborate, myths of exotic origins, such as the one recounted in the Ecclesiastical History of the English People, written by the Anglo-Saxon scholar Bede in AD731.
    • This claimed that the Picts migrated from Scythia (a historical region around the northern coast of the Black Sea) to northern Britain.
    • Other theories include an origin in Thrace (a historical region in south-east Europe) and islands to the north of Britain.

Female inheritance

    • This fascinating insight provides a glimpse into the demographic processes that have shaped genetic diversity and population structure in present-day populations.
    • Bede stated that when the Picts stopped off in Ireland before settling in Britain, they were allowed to marry local women on the condition that Pictish succession passed down the female line.
    • This is more consistent with female exogamy, where women marry outside their social group.
    • The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Patient, Neoplasm, Immune tolerance, Research, Sumathi Best Television Current Reporting Award, MSI-H, Therapy, Growth, Maintenance, SAN, PLOS, PLOS Genetics, Genetics, GLOBE, Squamous cell carcinoma, Safety, Pharmacokinetics, Securities Exchange Act of 1934, Poster, Terminology, Nature Genetics, Immunotherapy, Securities Act of 1933, 23andMe, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Cancer, Genome, Helios Techno Holding Co., Ltd., Security (finance), Society, CD200, SITC, MD, Nature, Myelocyte, Primary peritoneal carcinoma, Pharmaceutical industry, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.

Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

Retrieved on: 
Tuesday, July 12, 2022
Software, Radiology, Hardware, Pharmaceutical, Data Management, Oncology, Technology, Infectious Diseases, Genetics, Surgery, Clinical Trials, Biotechnology, Health, Sequence, Method, GenomeWeb, U.S. Securities and Exchange Commission, Neoplasm, College, Drug resistance, Leadership, Exome, Solution, Genetics, Mutation, LinkedIn, Genomics, Whole genome sequencing, Patient, CEO, Clinical Laboratory Improvement Amendments, Form, Form S-3, PSNL, College of American Pathologists, Patent, Database, Breast, Cancer, Nasdaq, Plasma, PLOS Genetics, Twitter, MRD, Genome, Immune system, NeXT, Recurrence, Efficiency, DNA, Family, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.
  • After a tumor has been surgically resected, it may be present at just a few parts per million.
  • To improve the chances of detecting a signal, data can be combined from several tumor mutation positions in a genome.
  • John West, CEO and co-founder of Personalis, and a co-inventor, said, Personalis was active in whole human genome sequencing very early on.

MolecuLight i:X® Receives FDA 510(k) Clearance for the Device's Ability to Detect Wounds Likely to Contain Pseudomonas aeruginosa (PA)

Retrieved on: 
Thursday, September 23, 2021
Debridement, CWS, Symposium, Wound healing, Ulcer, FDA, Multimedia, Patient, Hyperbaric medicine, Bacteria, Subclinical infection, PLOS Genetics, Pseudomonas aeruginosa, Technology, Food safety, Utility, SAWC, Foot, Fluorescence, RN, Medical imaging

The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.

Key Points: 
  • The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.
  • This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.
  • The MolecuLight i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of PA (>104 CFU/g).
  • This new FDA clearance recognizes the added benefit of the i:X in visualizing and differentiating Pseudomonas aeruginosa in wounds through the cyan fluorescence signal it produces on the images.

MolecuLight i:X® Receives FDA 510(k) Clearance for the Device's Ability to Detect Wounds Likely to Contain Pseudomonas aeruginosa (PA)

Retrieved on: 
Thursday, September 23, 2021
Debridement, CWS, Symposium, Wound healing, Ulcer, FDA, Patient, Hyperbaric medicine, Bacteria, Subclinical infection, PLOS Genetics, Pseudomonas aeruginosa, Technology, Food safety, Utility, SAWC, Foot, Fluorescence, RN, Medical imaging

TORONTO, Sept. 23, 2021 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received FDA 510(k) clearance for the detection of wounds containing clinically significant levels (>104 CFU/g) of Pseudomonas aeruginosa (PA) for the previously cleared MolecuLight i:X imaging device.  The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria. This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.  This augmented labeling is based on a detailed retrospective statistical analysis of over 350 patients.

Key Points: 
  • The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria.
  • This new FDA clearance supports the ability of the i:X device to increase the clinician's ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.
  • The MolecuLight i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of PA (>104 CFU/g).
  • This new FDA clearance recognizes the added benefit of the i:X in visualizing and differentiating Pseudomonas aeruginosa in wounds through the cyan fluorescence signal it produces on the images.